Schiffman JS, D'Avino AR, Prieto T, Pang Y, Fan Y, Rajagopalan S, Potenski C, Hara T, Suvà ML, Gawad C et al..  2024.  Defining heritability, plasticity, and transition dynamics of cellular phenotypes in somatic evolution.. Nat Genet. 56(10):2174-2184.

Reinartz R, Wang S, Kebir S, Silver DJ, Wieland A, Zheng T, Küpper M, Rauschenbach L, Fimmers R, Shepherd TM et al..  2017.  Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma.. Clin Cancer Res. 23(2):562-574.

Behling K, Maguire WF, Puebla JCarlos Ló, Sprinkle SR, Ruggiero A, O'Donoghue J, Gutin PH, Scheinberg DA, McDevitt MR.  2016.  Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma.. J Nucl Med. 57(10):1576-1582.

Thomas AA, Fisher JL, Rahme GJ, Hampton TH, Baron U, Olek S, Schwachula T, C Rhodes H, Gui J, Tafe LJ et al..  2015.  Regulatory T cells are not a strong predictor of survival for patients with glioblastoma.. Neuro Oncol. 17(6):801-9.

Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J et al..  2007.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.. Cancer Cell. 11(2):147-60.